DelveInsight Highlights Major Advances, Transformative Therapies, and 25+ Leading Players Wheeling the Lung Adenocarcinoma Clinical Trial Pipeline Landscape

By GlobeNewswire On May 24, 2023

The prevalence of lung adenocarcinoma has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of lung adenocarcinoma and the growing research and development activities to develop novel therapies to treat lung adenocarcinoma to drive the market. The companies developing the potential therapies in the last stage of development include BerGenBio, Onconova Therapeutics, Rain Oncology Inc, and several others.

New York, USA, May 24, 2023 (GLOBE NEWSWIRE) — DelveInsight Highlights Major Advances, Transformative Therapies, and 25+ Leading Players Wheeling the Lung Adenocarcinoma Clinical Trial Pipeline Landscape

DelveInsight’s ‘Lung Adenocarcinoma Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline lung adenocarcinoma therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space and future growth potential of the lung adenocarcinoma pipeline domain.

Key Takeaways from the Lung Adenocarcinoma Pipeline Report

DelveInsight’s lung adenocarcinoma pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for lung adenocarcinoma treatment.
Key lung adenocarcinoma companies such as BerGenBio, Innovent Biologics, Lantern Pharma Inc., Pionyr Immunotherapeutics Inc., Onconova Therapeutics, Inc., Pfizer, Chugai Pharmaceutical, Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Cantargia, Multitude Therapeutics Inc., Rain Oncology Inc., Bristol-Myers Squibb, and others are evaluating new lung adenocarcinoma drugs to improve the treatment landscape.
Promising lung adenocarcinoma pipeline therapies such as Bemcentinib, IBI188, LP-300, PY159, Rigosertib, PF-07220060, RO5126766, Spartalizumab, Neoantigen specific TCR-T cell drug, huCART-meso cells, IMU-201, CAN04, AMT-151, RAIN-32, MORAb-202, and others are under different phases of lung adenocarcinoma clinical trials.

In March 2023, The Lung Cancer Research Foundation (LCRF) announced a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody-drug conjugates (ADCs) to improve outcomes for people with lung cancer. Applications for these grants are being accepted through May 31, 2023. This collaboration seeks to support research to study HER2-directed and TROP2-directed ADCs including mechanism of action, biomarkers, and resistance mechanisms.
In February 2023, Ankyra Therapeutics announced that it has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson. The collaboration will focus on the advancement of Ankyra’s lead product candidate, ANK-101, an IL-12-based locally administered immunotherapy, as a potential treatment for lung cancer.
In October 2022, Scorpion Therapeutics, Inc. announced preclinical proof-of-concept data for STX-721, the Company’s first development candidate from its STX-EGFR-EXON-20 program. In the poster presented at EORTC-NCI-AACR, Scorpion scientists shared data from preclinical studies evaluating STX-721 across a broad panel of exon 20 mutant cell lines, with the high selectivity of osimertinib against EGFR T790M mutant cells used as a benchmark for EGFR mutant selectivity. In these studies, STX-721 demonstrated strong EGFR exon 20 mutant potency and selectivity in isogenic Ba/F3 models and human cancer cell lines, as well as signaling and biochemical assays. Importantly, the selectivity of STX-721 for EGFR exon 20 was observed to well exceed that of clinical-stage competitor benchmarks in each of these model systems, while also approaching the selectivity of osimertinib against EGFR L858R and exon 19 deletion mutations.
In December 2022, XtalPi, announced a strategic collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research of Singapore (A*STAR), to discover novel treatment candidates for non-small cell lung cancer (NSCLC).

Request a sample and discover the recent advances in lung adenocarcinoma treatment drugs @ Lung Adenocarcinoma Pipeline Report

The lung adenocarcinoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage lung adenocarcinoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the lung adenocarcinoma clinical trial landscape.

Lung Adenocarcinoma Overview

Lung adenocarcinoma is the most frequent type of primary lung cancer in the United States. It is classified as non-small cell lung cancer (NSCLC) and is strongly linked to prior smoking. While incidence and mortality have decreased, it remains the top cause of cancer death in the United States. Adenocarcinoma of the lung mainly develops from the mucosal glands and accounts for around 40% of all lung malignancies. It is the most common kind in those who have never smoked. Lung adenocarcinoma is most commonly found on the lung’s periphery and can also be found in scars or areas of chronic inflammation. Tobacco use is by far the most important risk factor for any type of lung cancer, including adenocarcinoma. Because tobacco smoke contains multiple carcinogens, primary or secondary exposure raises risk proportionally to the amount of exposure. Other lung adenocarcinoma risk factors include a family history of lung cancer and occupational exposure to other agents, such as silica, asbestos, radon, heavy metals, and diesel fumes. In 52% of cases, resulting genetic abnormalities in the p53 gene are the most common cause of carcinogenesis in NSCLC.

Find out more about lung adenocarcinoma treatment drugs @ Drugs for Lung Adenocarcinoma Treatment

A snapshot of the Lung Adenocarcinoma Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Bemcentinib	BerGenBio	Phase II	Axl receptor tyrosine kinase inhibitors; Virus internalisation inhibitors	NA
RAIN-32	Rain Oncology Inc	Phase II	Proto-oncogene protein c mdm2 inhibitors	Oral
Rigosertib	Onconova Therapeutics	Phase I/II	1 Phosphatidylinositol 3 kinase inhibitors; Microtubule protein inhibitors; Polo-like kinase 1 inhibitors; Ras signal transduction pathway inhibitors	Oral
PF-07220060	Pfizer	Phase I/II	Cyclin-dependent kinase 4 inhibitors	NA
Letaplimab (IBI188)	Innovent Biologics	Phase I	Antibody-dependent cell cytotoxicity; T lymphocyte stimulants	Intravenous
PY159	Pionyr Immunotherapeutics	Phase I	Triggering receptor expressed on myeloid cells 1 agonists	Intravenous

Learn more about the emerging lung adenocarcinoma pipeline therapies @ Lung Adenocarcinoma Clinical Trials

Lung Adenocarcinoma Therapeutics Assessment

The lung adenocarcinoma pipeline report proffers an integral view of the lung adenocarcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Lung Adenocarcinoma Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Subcutaneous, Oral
Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
Therapeutics Assessment By Mechanism of Action: Axl receptor tyrosine kinase inhibitors, Virus internalization inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Glutaredoxin modulators, Thioredoxin modulators, Triggering receptor expressed on myeloid cells 1 agonists, 1 Phosphatidylinositol 3 kinase inhibitors, Microtubule protein inhibitors, Polo-like kinase 1 inhibitors, Ras signal transduction pathway inhibitors, Cyclin-dependent kinase 4 inhibitors, Mitogen-activated protein kinase inhibitors, Mitogen-activated protein kinase kinase inhibitors, Raf kinase inhibitors
Key Lung Adenocarcinoma Companies: BerGenBio, Innovent Biologics, Lantern Pharma Inc., Pionyr Immunotherapeutics Inc., Onconova Therapeutics, Inc., Pfizer, Chugai Pharmaceutical, Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Cantargia, Multitude Therapeutics Inc., Rain Oncology Inc., Bristol-Myers Squibb, and others
Key Lung Adenocarcinoma Pipeline Therapies: Bemcentinib, IBI188, LP-300, PY159, Rigosertib, PF-07220060, RO5126766, Spartalizumab, Neoantigen specific TCR-T cell drug, huCART-meso cells, IMU-201, CAN04, AMT-151, RAIN-32, MORAb-202, and others

Dive deep into rich insights for new drugs for lung adenocarcinoma treatment, visit @ Lung Adenocarcinoma Drugs

Table of Contents

1.	Lung Adenocarcinoma Pipeline Report Introduction
2.	Lung Adenocarcinoma Pipeline Report Executive Summary
3.	Lung Adenocarcinoma Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Lung Adenocarcinoma Clinical Trial Therapeutics
6.	Lung Adenocarcinoma Pipeline: Late Stage Products (Pre-registration)
7.	Lung Adenocarcinoma Pipeline: Late Stage Products (Phase III)
8.	Lung Adenocarcinoma Pipeline: Mid Stage Products (Phase II)
9.	Lung Adenocarcinoma Pipeline: Early Stage Products (Phase I)
10.	Lung Adenocarcinoma Pipeline Therapeutics Assessment
11.	Inactive Products in the Lung Adenocarcinoma Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Lung Adenocarcinoma Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the lung adenocarcinoma pipeline therapeutics, reach out @ Lung Adenocarcinoma Treatment Drugs

Related Reports

Lung Adenocarcinoma Epidemiology

Lung Adenocarcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the lung adenocarcinoma epidemiology trends.

Lung Adenocarcinoma Market

Lung Adenocarcinoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lung adenocarcinoma companies, including Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Hoffmann-La Roche, Cantargia, among others.

Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-small cell lung cancer companies, including Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, among others.

Small-cell Lung Cancer Pipeline

Small-cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

Small Cell Lung Cancer Market

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

Other Trending Oncology Reports

Related Healthcare Blogs

Upcoming Oncological Drugs in 2023

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Checkpoint Inhibitor Refractory Cancer Market

Promising Oncolytic Virues Candidates in Pipeline

ENHERTU’s Journey in Cancer Treatment and Management

Potential of PD-1 and PD-L1 Inhibitors in Cancer Management

Evolving EGFR NSCLC Treatment Market Dynamics

Emerging Role of Digital Health in the Field of Oncology

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn

CONTACT: Contact Us Shruti Thakur  [email protected]  +1(919)321-6187  www.delveinsight.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.